Priovant`s Brepocitinib Nda For Dermatomyositis Accepted By FDA
03 Mar 2026 //
GLOBENEWSWIRE
Priovant Reports Positive Phase 2 Data For Brepocitinib
06 Feb 2026 //
GLOBENEWSWIRE
Roivant and Priovant`s drug show Promising Result in Rare Disease
17 Sep 2025 //
PRESS RELEASE
Roivant and Priovant to Host Investor Video Conference
09 Jun 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support